Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
World Journal of Urology|August 3, 2018
External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinomaLorenzo Marconi, Roderick de Bruijn, Erik van Werkhoven, et al.
Lancet (London, England)|September 13, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trialSumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, et al.
European Urology Oncology|March 14, 2020
Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerBenjamin Miron, Jean H Hoffman-Censits, Fern Anari, et al.
Urologic Oncology|June 25, 2023
Multiparametric MRI is not sufficient for prostate cancer staging: A single institutional experience validated by a multi-institutional regional collaborativeThenappan Chandrasekar, Andrew Denisenko, Vasil Mico, et al.
Spine|July 11, 2025
Patient Perceptions After Elective, Outpatient Lumbar Spine Surgery: Do Patients Prefer Same Day Discharge or an Overnight Stay?Tejas Subramanian, Stephane Owusu Sarpong, Chad Z Simon, et al.
Journal of the National Cancer Institute|May 3, 2020
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational ResearchToni K Choueiri, Michael B Atkins, Ziad Bakouny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2024
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)Daniel M Geynisman, Philip H Abbosh, Eric Ross, et al.
JAMA Oncology|November 22, 2019
Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney CancerSundeep Agrawal, Naomi B Haas, Mohammadhadi Bagheri, et al.
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Urologic Oncology|August 7, 2022
Practice trends for perioperative intravesical chemotherapy in upper tract urothelial carcinoma: Low but increasing utilization during minimally invasive nephroureterectomyAlexander P Kenigsberg, Gianpaolo Carpinito, Samuel A Gold, et al.
Pageof 8